(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 January 2012 (12.01.2012)

PCT

(10) International Publication Number
WO 2012/004299 A1

(51) **International Patent Classification**:
C07D 471/04 (2006.01) ***A61P 29/00*** (2006.01)
A61K 31/517 (2006.01)

(21) **International Application Number**:
PCT/EP2011/061393

(22) **International Filing Date**:
6 July 2011 (06.07.2011)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/361,589 6 July 2010 (06.07.2010) US

(71) **Applicant** *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **COOKE, Nigel Graham** [GB/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **FERNANDES GOMES DOS SANTOS, Paulo** [PT/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **GRAVELEAU, Nadege** [FR/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **HEBACH, Christina** [DE/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **HÖGENAUER, Klemens** [AT/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **HOLLINGWORTH, Gregory** [GB/GB]; Novartis Pharmaceuticals UK Limited, Horsham Research Centre, Wimblehurst Road, Horsham Sussex RH12 5AB (GB). **SMITH, Alexander Baxter** [GB/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **SOLDERMANN, Nicolas** [FR/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **STOWASSER, Frank** [DE/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **STRANG, Ross** [GB/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **TUFILLI, Nicola** [IT/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **VON MATT, Anette** [DE/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **WOLF, Romain** [LU/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **ZECRI, Frédéric** [FR/US]; Novartis Institutes for BioMedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US).

(74) **Agent**: **VON SPRECHER, Georg**; NOVARTIS PHARMA AG, Patent Department, CH-4002 Basel (CH).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*


Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title**: TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES



(I)

(57) **Abstract**: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R^1, R^2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.

WO 2012/004299 A1